ADNOC Gas Targets Up to $4B Profit in 2026 
Meta Ordered to Pay $567M Over Child Safety Violations in New Mexico 
Moderna Wins FDA Approval for mFLUSIVA mRNA Flu Vaccine for Adults 50+ 
Deutsche Bank Upgrades Persimmon to Buy After Strong First-Half Results 
AMP Shares Surge 13% After Strong Profit and A$150 Million Buyback 
Nvidia Seen Beating Q2 Targets as Vera Rubin Cycle Begins 
Apple Tests China’s CXMT Memory Chips for iPhones and MacBooks Amid AI Supply Crunch 
Alibaba Plans Revenue-Sharing Model for Qwen3.8-Max AI Commercial Users 
Sony, TSMC Eye $6.3 Billion Japan Chip Venture for Next-Gen Image Sensors 
Nvidia to Invest Up to $3 Billion in Blackstone-Backed Lancium 
UOB Q2 Net Profit Rises 10% as Wealth Management Growth Boosts Earnings 
Treasury Wine Estates Shares Jump as U.S. Overhaul Lifts FY2026 Outlook 
Goldman Sachs Sees US Stock Buybacks Outpacing Equity Issuance as AI Funding Rises 
DeepSeek to Raise AI API Prices as Demand for New Models Surges 
Airbnb Stock Jumps After Q2 Earnings Beat, Strong 2026 Outlook 
Delta Flight Makes Emergency Landing in Atlanta After Cockpit Fumes Reported 
Western Digital Q4 Earnings Beat Estimates as FY2027 Outlook Tops Expectations 
SAN DIEGO, Feb. 22, 2018 -- Cytori Therapeutics, Inc. (NASDAQ:CYTX) will provide a live webcast of its fourth quarter financial results and business update on Thursday, March 8, 2018 at 5:30 PM Eastern Time.
| The dial-in information is as follows: | |
| Dial-In Number: +1.877.402.3914 | |
| Conference ID: 9689618 | |
Prior to the webcast at approximately 4:30 PM Eastern Time on March 8th, Cytori will issue its fourth quarter earnings release which will review Cytori’s fourth quarter and annual performance. The webcast will be available both live and by replay two hours after the call in the “Webcasts” section of the company’s investor relations website.
About Cytori Therapeutics, Inc.
Cytori is a therapeutics company developing regenerative and oncologic therapies from its proprietary cell therapy and nanoparticle platforms for a variety of medical conditions. Data from preclinical studies and clinical trials suggest that Cytori Cell Therapy™ acts principally by improving blood flow, modulating the immune system, and facilitating wound repair. As a result, Cytori Cell Therapy™ may provide benefits across multiple disease states and can be made available to the physician and patient at the point-of-care through Cytori’s proprietary technologies and products. Cytori Nanomedicine™ is developing liposome encapsulated therapies for regenerative medicine and oncologic indications. For more information, visit www.cytori.com.
Cytori Therapeutics, Inc.
Tiago Girao, 1.858.458.0900
[email protected]
